November 20, 2017 10:20 AM ESTUpdated 10:36 AM
News Briefing

Pro­men­tis clos­es $26M round and en­ters clin­ic; Pelle­Phar­ma gets break­through/or­phan sta­tus; Shire ap­points Dit­trich as CFO

Brittany Meiling

→ Mil­wau­kee-based Pro­men­tis Phar­ma­ceu­ti­cals has closed the fi­nal tranche of its pre­vi­ous­ly-an­nounced $26 mil­lion Se­ries C …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times